Houlihan Lokey Advises Valkyrie Clinical Trials

Houlihan Lokey is pleased to announce that Valkyrie Clinical Trials (Valkyrie) has been acquired by Flourish Clinical Research (Flourish), a portfolio company of Genstar Capital, LP (Genstar). Houlihan Lokey served as the exclusive sellside financial advisor to Valkyrie.

Founded in 2021 by leading medical oncologist Dr. David Berz, Valkyrie provides cutting-edge cancer therapy to a highly diverse patient population and supports sponsors by furthering research in novel therapies and treatments. The company operates three sites in Los Angeles, serving a network of more than 200,000 cancer patients.

Headquartered in Apex, North Carolina, Flourish’s network of 30 sites and more than 160 investigators conducts studies spanning all phases of clinical trial research. The company is known for its deep medical expertise in several therapeutic areas and a reliable, predictable, and timely patient recruitment experience. With best-in-class technology, quality, and operations systems, Flourish is well positioned to best serve patients and its biopharma sponsor and CRO clients to advance clinical research in an efficient manner.

Genstar is a leading private equity firm that has been actively investing in high-quality companies for more than 30 years. Based in San Francisco, Genstar works in partnership with its management teams and its network of strategic advisors to transform its portfolio companies into industry-leading businesses. Genstar currently has approximately $50 billion in assets under management and targets investments focused on targeted segments of the financial services, software, healthcare, and industrials industries.

Houlihan Lokey’s Healthcare Group is among the largest and most active dedicated healthcare investment banking groups in the world. In 2024, the group closed 35 transactions and was ranked by LSEG (formerly Refinitiv) as the No. 1 M&A advisor globally for healthcare transactions under $1 billion.

RELATED: Healthcare, Mergers & Acquisitions